Latest news with #AnixaBiosciences
Yahoo
3 days ago
- Business
- Yahoo
Breast cancer vaccine moving to critical phase
(NewsNation) — Doctors are currently testing a vaccine for breast cancer they say can stop cancerous tumors from forming before they start. Breast cancer is the second-leading cause of cancer death in women younger than 50, according to the American Cancer Society. The number of younger women being diagnosed with the disease has increased 1.5% each year since 2012. The vaccine, being developed by biotech company Anixa Biosciences, is nearing the end of its phase one trials and moving on to round two. Dr. Amit Kumar, the CEO of Anixa, joined NewsNation's 'Elizabeth Vargas Reports' and said women in the trial responded well to the vaccine, and there are no safety concerns with it. How long does it take weight loss drugs to work? 'Our approach is not to try and deal with the underlying cause, our approach is to train the immune system to destroy those cancer cells as they arise,' Kumar said. 'We think that this is going to be a game-changer.' Kumar added that the eventual goal is to prevent cancer entirely, but to also prevent it in women who have already been through cancer and are worried about a recurrence. The vaccine will officially move to phase two of its trials after meetings with the U.S. Food and Drug Administration. Kumar said he hopes the vaccine will be available to women to prevent cancer within the next few years. 'What's better than treating breast cancer is preventing it,' Kumar said. 'If we can do this for breast cancer, we will do it for other cancers, as well.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
12-05-2025
- Business
- Yahoo
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
SAN JOSE, May 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone, Chief Development Officer of Anixa, will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 – June 3, 2025, in Chicago, Illinois. Lead author on the poster is Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy. Presentation Details: Title: Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA) Session: Developmental Therapeutics—Immunotherapy Session Type: Poster Session Date & Time: June 2, 2025, 1:30 PM – 4:30 PM CT Abstract ID: TPS2682 About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFOmcatelani@ View original content to download multimedia: SOURCE Anixa Biosciences, Inc. Sign in to access your portfolio
Yahoo
09-04-2025
- Business
- Yahoo
EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent
On Wednesday, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to Anixa Biosciences, Inc.'s (NASDAQ:ANIX) breast cancer vaccine technology. Cleveland Clinic has exclusively licensed the patent and others related to this technology to Anixa Biosciences. The patent will expand the scope of immunogenic compositions utilized in Anixa's breast cancer vaccine. Also Read: This newly allowed patent covers methods of immunizing patients against breast cancer by administering an immunogenic composition containing the human α-lactalbumin protein, a protein typically found in breast tissue during lactation but also expressed in certain breast cancers. Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated, "This patent strengthens our intellectual property portfolio and highlights the novelty of our breast cancer vaccine. Our intellectual property portfolio includes multiple issued and pending patents in the U.S. and international jurisdictions." In March, the USPTO issued a Notice of Allowance for a key patent application covering Anixa Biosciences ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting the Anti-Mullerian Hormone Receptor, Type II (AMHR2), a target for ovarian cancer prevention and treatment. Anixa's ovarian cancer vaccine is being developed in collaboration with Cleveland Clinic and the National Cancer Institute. The allowed claims include methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide, specifically the extracellular domain of human AMHR2, to elicit an AMHR2-specific immune response. Price Action: ANIX stock closed at $2.38 on Tuesday. Read Next:Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Associated Press
10-03-2025
- Business
- Associated Press
Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
SAN JOSE, Calif., March 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2025 Annual Meeting of Stockholders (the 'Meeting') on Thursday, March 20, 2025 at 10:00 a.m. Pacific Time in a virtual format. Following the formal business and voting portion of the Meeting, Anixa Chairman and CEO Dr. Amit Kumar, will deliver an investor presentation and corporate update, followed by a question-and-answer session. All interested parties may attend the Meeting. All parties may access the Meeting online at About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against 'retired' proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words 'believes,' 'expects,' 'intends,' 'plans,' 'anticipates,' 'likely,' 'will' and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in 'Item 1A - Risk Factors' and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact: Mike Catelani 408-708-9808
Yahoo
27-02-2025
- Business
- Yahoo
Spotlight On February 2025's Promising Penny Stocks
The U.S. stock market is experiencing mixed signals as investors process recent earnings reports and policy announcements, with the Dow Jones seeing gains while the S&P 500 and Nasdaq face slight declines. Amid these fluctuations, penny stocks present a unique opportunity for investors seeking growth at lower price points. Although often associated with smaller or newer companies, these stocks can offer significant potential when supported by strong financials and solid fundamentals. Name Share Price Market Cap Financial Health Rating QuantaSing Group (NasdaqGM:QSG) $3.08 $128.29M ★★★★★★ TETRA Technologies (NYSE:TTI) $3.93 $540.42M ★★★★☆☆ Safe Bulkers (NYSE:SB) $3.89 $410.67M ★★★★☆☆ BAB (OTCPK:BABB) $0.8206 $6.54M ★★★★★☆ Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $67.38M ★★★★★★ North European Oil Royalty Trust (NYSE:NRT) $4.41 $41.82M ★★★★★★ Permianville Royalty Trust (NYSE:PVL) $1.43 $47.52M ★★★★★★ PHX Minerals (NYSE:PHX) $4.16 $154.05M ★★★★★☆ Smith Micro Software (NasdaqCM:SMSI) $1.35 $23.41M ★★★★★☆ CBAK Energy Technology (NasdaqCM:CBAT) $0.8354 $74.1M ★★★★★☆ Click here to see the full list of 732 stocks from our US Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Anixa Biosciences, Inc. is a biotechnology company that develops therapies and vaccines targeting critical unmet needs in oncology, with a market cap of approximately $95.30 million. Operations: Anixa Biosciences, Inc. currently does not report any revenue segments. Market Cap: $95.3M Anixa Biosciences, Inc., with a market cap of approximately US$95.30 million, is pre-revenue and focuses on developing innovative therapies in oncology. The company has a strong cash position, with short-term assets of US$21.4 million exceeding both its long-term liabilities and short-term liabilities. Anixa's management team is seasoned, averaging 7.6 years in tenure, which provides stability as the company navigates its clinical trials for CAR-T therapy targeting ovarian cancer through a partnership with Moffitt Cancer Center. Recent protocol amendments have expanded trial eligibility and dosing flexibility, potentially enhancing therapeutic impact assessment for diverse patient groups. Click to explore a detailed breakdown of our findings in Anixa Biosciences' financial health report. Evaluate Anixa Biosciences' prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Huize Holding Limited operates an online insurance product and service platform in the People's Republic of China, with a market cap of $32.44 million. Operations: The company's revenue is primarily derived from its insurance brokerage services, totaling CN¥1198.97 million. Market Cap: $32.44M Huize Holding Limited, with a market cap of US$32.44 million, operates an online insurance platform and recently launched "PrimeMed," a mid-tier medical insurance product in collaboration with partners. While the company's revenue reached CN¥369.7 million for Q3 2024, net income declined to CN¥18.65 million from the previous year. The stock underwent a 1:5 split in December 2024, reflecting its volatile nature. Despite low return on equity at 5.1%, Huize's debt levels are well-managed and covered by operating cash flow (680%). Analysts forecast substantial earnings growth, although recent profit margins have decreased to 1.7%. Click here and access our complete financial health analysis report to understand the dynamics of Huize Holding. Gain insights into Huize Holding's future direction by reviewing our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: 4D Molecular Therapeutics, Inc. is a clinical-stage biotherapeutics company focused on developing genetic medicines with its therapeutic vector evolution platform in the Netherlands and the United States, with a market cap of $209.87 million. Operations: The company generates revenue primarily from its biotechnology segment, totaling $0.017 million. Market Cap: $209.87M 4D Molecular Therapeutics, with a market cap of US$209.87 million, focuses on genetic medicines but remains pre-revenue with minimal income of US$17K. The company is advancing its 4D-150 program for wet AMD and DME, aiming to reduce treatment burdens through innovative therapies. Recent positive interim data and strategic alignment with the FDA highlight potential growth avenues. Despite high volatility and unprofitability, 4DMT benefits from a strong cash position covering liabilities and no debt obligations. The management team is experienced, though earnings are forecasted to decline over the next three years without expected profitability soon. Take a closer look at 4D Molecular Therapeutics' potential here in our financial health report. Learn about 4D Molecular Therapeutics' future growth trajectory here. Reveal the 732 hidden gems among our US Penny Stocks screener with a single click here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:ANIX NasdaqGM:HUIZ and NasdaqGS:FDMT. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
